Anzeige
Mehr »
Login
Montag, 07.10.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
EXPLOSIVES WACHSTUM voraus: URAN-AKTIEN vor dem großen Durchbruch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
446 Leser
Artikel bewerten:
(2)

Arsenal Capital Partners: Arsenal Acquires ATP Group from Bregal Unternehmerkapital

NEW YORK and LUXEMBOURG, Feb. 1, 2022 /PRNewswire/ -- Bregal Unternehmerkapital ("BU") announced the sale of ATP Group ("ATP"), a leading manufacturer of water-based adhesive tapes, to Arsenal Capital Partners ("Arsenal"). The terms of the transaction were not disclosed.

ATP, headquartered in Wollerau, Switzerland, with production sites in Bad Kreuzburg (Germany), Philadelphia (USA), and Ipswich (United Kingdom), employs approximately 460 staff and has its own R&D capabilities to develop single- and double-sided high-performing industrial adhesive tapes, tailored individually to specific customer requirements. The products are manufactured on state-of-the-art coating machines and utilized by customers in a broad range of medical, mobility, construction, electronics, industrial, and graphics applications. Furthermore, being water-based, ATP's high-quality adhesive tapes are also considerably more environmentally friendly than other adhesive solutions.

"We appreciate the hands-on support that Bregal Unternehmerkapital has provided us during our partnership," said Daniel Heini, President and Chief Executive Officer of ATP. "Our commitment to environmentally friendly solutions provides a long-term growth opportunity for ATP. We are excited to partner with Arsenal to continue our global expansion and become the partner of choice of specialty water-based tapes to our international customer base."

Felix Werdin, a Partner of BU, added, "We appreciate the continuous development of ATP by Daniel Heini and the entire ATP management team into the leading water-based adhesive tapes manufacturer. We are proud to have supported the team to accelerate the company's overseas expansion over the past years, and we are convinced that ATP is well positioned for the next stage of its impressive growth trajectory with its new partner Arsenal."

Roy Seroussi, an Investment Partner of Arsenal, commented, "We see a significant unmet need for environmentally friendly tapes across technically demanding end markets, and ATP is at the forefront of this substitution trend. Together with Daniel and ATP's management team, Arsenal intends to accelerate the company's global growth strategy through innovation, manufacturing extensions, and acquisitions."

Morgan Stanley & Co. LLC acted as exclusive financial advisor to Bregal Unternehmerkapital and ATP. Houlihan Lokey served as a financial advisor to Arsenal.

About ATP Group

Founded in 1988 and headquartered in Wollerau, Switzerland, ATP is the leading developer, manufacturer, and supplier of all types of specialized, single-sided and double-sided water based adhesive tapes. ATP's business model is driven by developing customized and bespoke products for its customers. The company has a well-established global distribution network and serves customers across 60+ countries worldwide. ATP pioneered water-based adhesive tape technology, which is significantly more environmentally friendly. For more information, visit www.atp-ag.com.

About Bregal Unternehmerkapital

BU is part of a family-owned business that has grown over several generations. The BU funds invest in mid-sized companies in the DACH region and Northern Italy across a wide range of sectors with a focus on market leaders and "hidden champions" with strong management teams and outbreak potential. With patient capital, entrepreneurial expertise and a partnership approach, our team works closely with entrepreneurs to develop, internationalize, and digitalize portfolio companies, and to help them generate sustainable value on a responsible basis.

About Arsenal Capital Partners

Arsenal is a leading private equity firm that specializes in investments in middle-market industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of more than $10 billion, has completed more than 250 platform and add-on investments, and achieved more than 30 realizations. Arsenal invests in industry sectors in which the firm has significant prior knowledge and experience. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add. Visit www.arsenalcapital.com for more information.

Media Contact
Jackie Schofield
Jschofield@prosek.com

© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.